SciClone Pharmaceuticals (NASDAQ: SCLN) and Horizon Pharma (NASDAQ:HZNP) are both pharmaceuticals – nec companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Valuation & Earnings

This table compares SciClone Pharmaceuticals and Horizon Pharma’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SciClone Pharmaceuticals N/A N/A N/A $0.86 12.97
Horizon Pharma $981.12 million 2.49 -$166.83 million ($3.04) -4.90

SciClone Pharmaceuticals has higher earnings, but lower revenue than Horizon Pharma. Horizon Pharma is trading at a lower price-to-earnings ratio than SciClone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


This table compares SciClone Pharmaceuticals and Horizon Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SciClone Pharmaceuticals 27.39% 20.24% 18.42%
Horizon Pharma -45.28% 20.22% 5.35%

Institutional and Insider Ownership

72.8% of SciClone Pharmaceuticals shares are held by institutional investors. Comparatively, 86.6% of Horizon Pharma shares are held by institutional investors. 5.2% of SciClone Pharmaceuticals shares are held by company insiders. Comparatively, 3.2% of Horizon Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for SciClone Pharmaceuticals and Horizon Pharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SciClone Pharmaceuticals 0 1 0 0 2.00
Horizon Pharma 0 2 9 0 2.82

SciClone Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 25.56%. Horizon Pharma has a consensus price target of $18.64, suggesting a potential upside of 25.08%. Given SciClone Pharmaceuticals’ higher possible upside, research analysts plainly believe SciClone Pharmaceuticals is more favorable than Horizon Pharma.


SciClone Pharmaceuticals beats Horizon Pharma on 7 of the 11 factors compared between the two stocks.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company’s marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Receive News & Ratings for SciClone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals and related companies with's FREE daily email newsletter.